ObsEva Starts Proof-of-concept Study of Compound to Prevent Premature Births
ObsEva has started a proof-of-concept clinical trial of its compound OBE022’s ability to prevent or delay premature births, which are associated with the development of cerebral palsy and other neurological conditions. The population in the Phase 2a study, called PROLONG, will be women who start labor 24 to 34 weeks…